Ameriprise’s Bioventus BVS Stock Holding History

Ameriprise’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32,457	Closed	-$34.7K	–	3919
2023 Q1	$34.7K	Buy	+32,457	New	+$62.1K	﹤0.01%	3887
2021 Q3	–	Sell	-12,096	Closed	-$110K	–	3864
2021 Q2	$110K	Buy	+12,096	New	+$195K	﹤0.01%	3815

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameriprise's BVS Position: Q2 2023 in Review

Ameriprise sold out of Bioventus (BVS) in Q2 2023, closing a stake of 32,457 shares — an estimated $34.7K sold.

Ameriprise first reported a position in BVS in Q2 2021 and held it in 2 quarters. The position peaked at $110K in Q2 2021. 66 funds tracked by Wall St. Rank hold BVS as of Q2 2023.

Ameriprise reported no remaining Bioventus position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 32,457 Bioventus shares in Q2 2023, an estimated $34.7K.
Ameriprise first reported a position in Bioventus in Q2 2021 and held it in 2 quarters.
Ameriprise's Bioventus position peaked at $110K in Q2 2021.
66 funds tracked by Wall St. Rank held Bioventus as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.